CNSX:IME

12144 Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume145,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

12144 (CNSX:IME) Vs. AKU, LXG, SQD, SVA, GEN, and LMD

Should you be buying IME stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to 12144, including Akumin (AKU), LexaGene (LXG), SQI Diagnostics (SQD), Sernova (SVA), GeneNews (GEN), and LED Medical Diagnostics (LMD).

Akumin (TSE:AKU) and 12144 (CNSX:IME) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Akumin and 12144, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin01102.50
121440000N/A

Akumin presently has a consensus price target of C$4.25, suggesting a potential upside of 8.70%.

Profitability

This table compares Akumin and 12144's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
12144N/AN/AN/A

Earnings and Valuation

This table compares Akumin and 12144's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminC$246.08 million1.10C$-25,263,475.00C($0.37)-10.71
12144N/AN/AN/AN/AN/A

12144 has lower revenue, but higher earnings than Akumin.

Summary

Akumin beats 12144 on 2 of the 2 factors compared between the two stocks.

12144 (CNSX:IME) and LexaGene (CVE:LXG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for 12144 and LexaGene, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
121440000N/A
LexaGene0000N/A

Profitability

This table compares 12144 and LexaGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
12144N/AN/AN/A
LexaGeneN/AN/AN/A

Valuation & Earnings

This table compares 12144 and LexaGene's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
12144N/AN/AN/AN/AN/A
LexaGeneN/AN/AN/AC($0.12)-6.22

12144 (CNSX:IME) and SQI Diagnostics (CVE:SQD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for 12144 and SQI Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
121440000N/A
SQI Diagnostics0000N/A

Profitability

This table compares 12144 and SQI Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
12144N/AN/AN/A
SQI DiagnosticsN/AN/AN/A

Valuation & Earnings

This table compares 12144 and SQI Diagnostics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
12144N/AN/AN/AN/AN/A
SQI DiagnosticsC$977,000.00108.10C$-12,264,984.00C($0.04)-8.61

12144 has higher earnings, but lower revenue than SQI Diagnostics.

Summary

SQI Diagnostics beats 12144 on 1 of the 1 factors compared between the two stocks.

12144 (CNSX:IME) and Sernova (CVE:SVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for 12144 and Sernova, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
121440000N/A
Sernova0000N/A

Profitability

This table compares 12144 and Sernova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
12144N/AN/AN/A
SernovaN/AN/AN/A

Valuation & Earnings

This table compares 12144 and Sernova's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
12144N/AN/AN/AN/AN/A
SernovaN/AN/AN/AC($0.03)-55.19

12144 (CNSX:IME) and GeneNews (TSE:GEN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for 12144 and GeneNews, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
121440000N/A
GeneNews0000N/A

Profitability

This table compares 12144 and GeneNews' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
12144N/AN/AN/A
GeneNewsN/AN/AN/A

Valuation & Earnings

This table compares 12144 and GeneNews' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
12144N/AN/AN/AN/AN/A
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A

12144 has higher earnings, but lower revenue than GeneNews.

Summary

GeneNews beats 12144 on 1 of the 1 factors compared between the two stocks.

12144 (CNSX:IME) and LED Medical Diagnostics (CVE:LMD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for 12144 and LED Medical Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
121440000N/A
LED Medical Diagnostics0000N/A

Profitability

This table compares 12144 and LED Medical Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
12144N/AN/AN/A
LED Medical DiagnosticsN/AN/AN/A

Valuation & Earnings

This table compares 12144 and LED Medical Diagnostics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
12144N/AN/AN/AN/AN/A
LED Medical DiagnosticsC$14.96 million1.04C$-1,512,615.00C($0.04)-10.26

12144 has higher earnings, but lower revenue than LED Medical Diagnostics.

Summary

LED Medical Diagnostics beats 12144 on 1 of the 1 factors compared between the two stocks.


12144 Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AKU
Akumin
0.7$3.91flatC$270.63 millionC$246.08 million-10.71
LXG
LexaGene
0.5$0.74flatC$83.27 millionN/A-6.22News Coverage
SQD
SQI Diagnostics
0.9$0.31flatC$52.59 millionC$977,000.00-8.61Gap Up
SVA
Sernova
0.5$1.49flatC$31.35 millionN/A-55.19News Coverage
GEN
GeneNews
0.5N/AN/AC$24.65 millionC$234,592.00-2.21
LMD
LED Medical Diagnostics
0.4$0.40flatC$15.51 millionC$14.96 million-10.26Gap Down
VPT
VentriPoint Diagnostics
0.6$0.57flatC$5.58 millionC$37,517.00-17.27News Coverage
IDL
Imaging Dynamics
0.4$0.08flatC$4.13 millionC$378,253.00-3.95Gap Down
DXD
3D Signatures
0.5$0.04flatC$2.66 millionN/A-0.91Gap Down
MBI
Med Biogene
0.5$0.05flatC$795,000.00N/A-7.50Gap Up
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.